aldosterone has been researched along with fumarates in 37 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (10.81) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (18.92) | 29.6817 |
| 2010's | 25 (67.57) | 24.3611 |
| 2020's | 1 (2.70) | 2.80 |
| Authors | Studies |
|---|---|
| Hess, JJ; Maffly, RH; Taylor, A | 1 |
| Greengard, P; Psychoyos, S; Tallan, HH | 1 |
| Aupetit, B; Desgrez, P; Legrand, JC; Malméjac, A; Zogbi, F | 1 |
| Desgrez, P; Legrand, JC; Zogbi, F | 1 |
| Brunner, HR; Jensen, C; Nussberger, J; Wuerzner, G | 1 |
| Azizi, M; Bissery, A; Bura-Rivière, A; Camisasca, RP; Guyenne, TT; Ménard, J; Vaidyanathan, S | 1 |
| Athyros, VG; Kakafika, AI; Karagiannis, A; Mikhailidis, DP; Tziomalos, K | 1 |
| Gilbert, RE; Kelly, DJ; Moe, G; Naik, G; Zhang, Y | 1 |
| Bobillier, A; Gardner, R; Hillier, C; MacFadyen, R; Mann, J; McDonagh, T; McMurray, J; Murdoch, D; Seed, A | 1 |
| Bomback, AS; Toto, R | 1 |
| Dalla Vestra, M; Masiero, A; Simioni, N | 1 |
| Rao, MS | 1 |
| Itabashi, M; Kojima, C; Moriyama, T; Nitta, K; Ogawa, T; Sugiura, H; Takei, T; Tsuchiya, K; Tsuruta, Y; Uchida, K | 1 |
| Derbentseva, EA; Dralova, OV; Ermolaeva, AS; Maksimov, ML; Starodubtsev, AK | 1 |
| Campbell, DJ; Gilbert, RE; Kelly, DJ; McCarthy, DJ; Shi, W; Smyth, GK; Zhang, Y | 1 |
| Appelbaum, E; Dahlöf, B; Desai, A; Lukashevich, V; Pouleur, AC; Prescott, MF; Smith, BA; Solomon, SD; Uno, H | 1 |
| Gimpelewicz, CR; Latini, R; Maggioni, AP; McMurray, JJ; Pitt, B; Sidik, NP; Solomon, SD; Wright, M | 1 |
| Hans-Henrik, P; Hollenberg, NK; Lewis, EJ; Lewis, JB; Persson, F; Rossing, P | 1 |
| Barkoudah, E; Danser, AH; Fisher, ND; Hollenberg, NK; Moukarbel, GV; Nussberger, J | 1 |
| Janka, R; Ott, C; Raff, U; Ritt, M; Schmieder, RE; Schneider, MP; Uder, M; Veelken, R; Ziegler, T | 1 |
| Appelbaum, E; Dahlof, B; Pouleur, AC; Prescott, M; Smith, B; Solomon, SD; Takeuchi, M; Vardeny, O; Verma, A | 1 |
| Akasaka, T; Imanishi, T; Ino, Y; Ishibashi, K; Kashiwagi, M; Kitabata, H; Komukai, K; Orii, M; Ozaki, Y; Shimamura, K; Shiono, Y; Sougawa, H; Tanimoto, T; Tsujioka, H | 1 |
| Ferrario, CM; Habibi, J; Hayden, MR; Locher, B; Nistala, R; Pulakat, L; Sinak, C; Sowers, JR; Whaley-Connell, A | 1 |
| Abe, M; Fujii, Y; Ito, M; Maruyama, N; Okada, K; Soma, M; Suzuki, H; Yoshida, Y | 1 |
| Abe, M; Baba, S; Inoshita, A; Maruyama, N; Okada, K; Soma, M; Suzuki, H; Takashima, H | 1 |
| Matavelli, LC; Siragy, HM | 1 |
| Ardhanari, S; DeMarco, VG; Ferrario, CM; Habibi, J; Hayden, MR; Krueger, C; Pulakat, L; Rehmer, N; Sowers, JR; Whaley-Connell, A | 1 |
| Derosa, G; Fogari, R; Maffioli, P; Mugellini, A; Perrone, T; Preti, P; Zoppi, A | 1 |
| Bode, C; Braunwald, E; Brunel, PC; Hoffman, EB; Morrow, DA; Prescott, MF; Ren, F; Rifai, N; Scirica, BM; Swedberg, K; Udell, JA | 1 |
| Fukuda, S; Sato, A | 1 |
| Endo, M; Fukuda, N; Kobayashi, N; Matsuda, H; Matsumoto, K; Matsumoto, T; Nishiyama, A; Saito, K; Soma, M; Ueno, T; Wang, X; Zhou, X | 1 |
| Fujimoto, N; Ichikawa, T; Ishikawa, E; Ito, G; Ito, M; Ito, T; Nomura, S; Okubo, S | 1 |
| Akasaka, T; Imanishi, T; Ino, Y; Kubo, T; Nishiguchi, T; Orii, M; Ozaki, Y; Shimamura, K; Shiono, Y; Tanimoto, T; Teraguchi, I; Yamaguchi, T; Yamano, T | 1 |
| Azizi, M; Balcarek, J; Bryson, C; Danser, AH; Garrelds, IM; Gregg, R; Griffith, SG; McGeehan, G; Ménard, J; Reeves, RA; Sevá Pessôa, B | 1 |
| Batenburg, WW; Bouhuizen, AM; Danser, AH; Garrelds, IM; Leijten, FP; Musterd-Bhaggoe, U; Peutz-Kootstra, CJ; te Riet, L; van den Heuvel, M; van Esch, JH; van Veghel, R | 1 |
| Ando, T; Bokuda, K; Ichihara, A; Itoh, H; Morimoto, S; Seki, Y; Shimizu, S; Watanabe, D; Yatabe, J; Yatabe, M | 1 |
| Aono, D; Demura, M; Hashimoto, A; Higashitani, T; Karashima, S; Kometani, M; Konishi, S; Takeda, Y; Yoneda, T | 1 |
4 review(s) available for aldosterone and fumarates
| Article | Year |
|---|---|
Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?
Topics: Administration, Oral; Aldosterone; Amides; Angiotensin II; Animals; Antihypertensive Agents; Enzyme Activation; Enzyme Reactivators; Fumarates; Heart Failure; Humans; Hypertension; Randomized Controlled Trials as Topic; Renin; Renin-Angiotensin System; Vasoconstrictor Agents | 2007 |
Dual blockade of the renin-angiotensin-aldosterone system: beyond the ACE inhibitor and angiotensin-II receptor blocker combination.
Topics: Aldosterone; Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fumarates; Humans; Kidney Diseases; Receptors, Mineralocorticoid; Renin-Angiotensin System | 2009 |
Aliskiren: a new inhibitor of renin-angiotensin aldosterone system activity.
Topics: Aldosterone; Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Clinical Trials as Topic; Diabetic Nephropathies; Double-Blind Method; Drug Therapy, Combination; Fumarates; Humans; Hypertension; Randomized Controlled Trials as Topic; Renin; Renin-Angiotensin System | 2009 |
Inhibition of the renin angiotensin aldosterone system: focus on aliskiren.
Topics: Aldosterone; Amides; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Fumarates; Mineralocorticoid Receptor Antagonists; Renin-Angiotensin System | 2010 |
16 trial(s) available for aldosterone and fumarates
| Article | Year |
|---|---|
Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril.
Topics: Administration, Oral; Adult; Aldosterone; Amides; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Enalapril; Fumarates; Heart Rate; Humans; Male; Potassium; Renin; Renin-Angiotensin System; Sodium | 2002 |
Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption.
Topics: Administration, Oral; Adolescent; Adult; Aldosterone; Amides; Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Cross-Over Studies; Drug Synergism; Feedback, Physiological; Fumarates; Humans; Male; Renin; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2004 |
Neurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure.
Topics: Aged; Aldosterone; Amides; Analysis of Variance; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Female; Fumarates; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Ramipril; Renin; Statistics, Nonparametric; Treatment Outcome | 2007 |
Beneficial effect of aliskiren combined with olmesartan in reducing urinary protein excretion in patients with chronic kidney disease.
Topics: Adult; Aldosterone; Amides; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Creatinine; Drug Therapy, Combination; Female; Fumarates; Glomerular Filtration Rate; Humans; Imidazoles; Male; Middle Aged; Olmesartan Medoxomil; Proteinuria; Renal Insufficiency, Chronic; Renin; Tetrazoles; Young Adult | 2012 |
Suppression of aldosterone mediates regression of left ventricular hypertrophy in patients with hypertension.
Topics: Aldosterone; Amides; Antihypertensive Agents; Blood Pressure; Demography; Female; Fumarates; Heart Ventricles; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Organ Size; Systole | 2011 |
Impact of aliskiren treatment on urinary aldosterone levels in patients with type 2 diabetes and nephropathy: an AVOID substudy.
Topics: Aldosterone; Amides; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Fumarates; Humans; Male; Middle Aged; Renin | 2012 |
Renal responses to three types of renin-angiotensin system blockers in patients with diabetes mellitus on a high-salt diet: a need for higher doses in diabetic patients?
Topics: Aldosterone; Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Blood Pressure; Captopril; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fumarates; Humans; Irbesartan; Kidney; Male; Middle Aged; Renin-Angiotensin System; Sodium Chloride, Dietary; Tetrazoles; Treatment Outcome | 2011 |
Influence of diabetes on efficacy of aliskiren, losartan or both on left ventricular mass regression.
Topics: Aldosterone; Amides; Antihypertensive Agents; Biomarkers; Blood Pressure; Diabetes Complications; Female; Fumarates; Heart Ventricles; Humans; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Organ Size; Renin; Treatment Outcome | 2012 |
Additive renoprotective effects of aliskiren on angiotensin receptor blocker and calcium channel blocker treatments for type 2 diabetic patients with albuminuria.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Aged; Albuminuria; Aldosterone; Amides; Amlodipine; Angiotensin II Type 2 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Calcium Channel Blockers; Deoxyguanosine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Fatty Acid-Binding Proteins; Female; Fumarates; Glomerular Filtration Rate; Glycated Hemoglobin; Humans; Male; Middle Aged; Renin; Telmisartan; Young Adult | 2012 |
Efficacy analysis of the renoprotective effects of aliskiren in hypertensive patients with chronic kidney disease.
Topics: Aged; Albuminuria; Aldosterone; Amides; Antihypertensive Agents; Biomarkers; Blood Pressure; Diabetic Nephropathies; Drug Therapy, Combination; Female; Fumarates; Glomerular Filtration Rate; Humans; Hypertension; Japan; Kidney; Male; Middle Aged; Prospective Studies; Renal Insufficiency, Chronic; Renin; Renin-Angiotensin System; Time Factors; Treatment Outcome | 2013 |
Time course of antiproteinuric effect of aliskiren in arterial hypertension associated with type 2 diabetes and microalbuminuria.
Topics: Adult; Aged; Albumins; Albuminuria; Aldosterone; Amides; Antihypertensive Agents; Arterial Pressure; Biomarkers; Blood Pressure Monitoring, Ambulatory; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fumarates; Humans; Hypertension; Male; Middle Aged; Prospective Studies; Ramipril; Renin; Single-Blind Method; Treatment Outcome | 2013 |
Effect of aldosterone breakthrough on albuminuria during treatment with a direct renin inhibitor and combined effect with a mineralocorticoid receptor antagonist.
Topics: Aged; Albuminuria; Aldosterone; Amides; Blood Pressure; Dose-Response Relationship, Drug; Drug Therapy, Combination; Eplerenone; Female; Fumarates; Humans; Hypertension; Incidence; Longitudinal Studies; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Renin; Renin-Angiotensin System; Spironolactone; Time Factors | 2013 |
Effects of aliskiren on blood pressure and humoral factors in hypertensive hemodialysis patients previously on angiotensin II receptor antagonists.
Topics: Adult; Aged; Aldosterone; Amides; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Female; Fumarates; Humans; Hypertension; Male; Middle Aged; Natriuretic Peptide, Brain; Renal Dialysis; Renin | 2014 |
Effect of direct renin inhibitor on left ventricular remodeling in patients with primary acute myocardial infarction.
Topics: Aged; Aldosterone; Amides; Angiotensin II Type 2 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Female; Fumarates; Humans; Male; Middle Aged; Myocardial Infarction; Renin; Ventricular Remodeling | 2014 |
Multiple ascending dose study with the new renin inhibitor VTP-27999: nephrocentric consequences of too much renin inhibition.
Topics: Adolescent; Adult; Aldosterone; Amides; Angiotensin II; Blood Pressure; Carbamates; Dose-Response Relationship, Drug; Female; Fumarates; Hemodynamics; Humans; Kidney; Male; Middle Aged; Piperidines; Renin; Young Adult | 2014 |
Greater reductions in plasma aldosterone with aliskiren in hypertensive patients with higher soluble (Pro)renin receptor level.
Topics: Aged; Aldosterone; Amides; Antihypertensive Agents; Blood Pressure; Female; Fumarates; Humans; Hypertension; Kidney; Kidney Function Tests; Male; Middle Aged; Receptors, Cell Surface; Renal Insufficiency, Chronic; Renin-Angiotensin System; Vacuolar Proton-Translocating ATPases; Vascular Stiffness | 2018 |
17 other study(ies) available for aldosterone and fumarates
| Article | Year |
|---|---|
On the effects of tricarboxylic acid cycle intermediates on sodium transport by the toad bladder.
Topics: Acetates; Aldosterone; Animals; Biological Transport, Active; Bufo marinus; Citric Acid Cycle; Drug Synergism; Fumarates; Hydrogen-Ion Concentration; Ketoglutaric Acids; Kinetics; Sodium; Succinates; Time Factors; Urinary Bladder | 1974 |
Aldosterone synthesis by adrenal mitochondria. II. The effect of citric acid cycle intermediates; identification of the soluble stimulatory factor as fumarase.
Topics: Adrenal Glands; Aldosterone; Animals; Anura; Citrates; Corticosterone; Fumarates; Hydro-Lyases; In Vitro Techniques; Ketoglutaric Acids; Malates; Mitochondria; NADP; Oxaloacetates; Pyruvates; Succinates | 1967 |
[Synthesis in vitro of 18-hydroxycorticosterone and aldosterone by 3 adenomas of the adrenal glomerula zone (Conn's syndrome) I. Conversion output].
Topics: Adenoma; Adrenal Gland Neoplasms; Aldosterone; Carbon Isotopes; Chromatography, Paper; Citric Acid Cycle; Corticosterone; Desoxycorticosterone; Fumarates; Glucosephosphate Dehydrogenase; Hexosephosphates; Humans; Hyperaldosteronism; Mitochondria; NADP; Pregnanes; Sterols; Tritium | 1969 |
[Synthesis in vitro of 18 hydroxycorticosterone and aldosterone by 3 adenomas of the adrenal glomerula zone (conn's syndrome) II. Metabolic routes].
Topics: Adenoma; Adrenal Gland Neoplasms; Aldosterone; Carbon Isotopes; Corticosterone; Desoxycorticosterone; Fumarates; Glucosephosphate Dehydrogenase; Hexosephosphates; Humans; Hyperaldosteronism; NADP; Pregnanes; Sterols; Tritium | 1969 |
Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats.
Topics: Aldosterone; Amides; Animals; Body Weight; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Female; Fumarates; Kidney; Organ Size; Rats; Rats, Inbred Strains; Renin | 2007 |
[Correction of aldosterone level as marker of RAAS dysfunction in patients with arterial hypertension degree II-III and chronic kidney diseases].
Topics: Aged; Aldosterone; Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biomarkers; Drug Therapy, Combination; Enalapril; Female; Fumarates; Humans; Hypertension; Indapamide; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2011 |
Aliskiren increases bradykinin and tissue kallikrein mRNA levels in the heart.
Topics: Aldosterone; Amides; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Body Weight; Bradykinin; Female; Fumarates; Heart; Kallikreins; Kidney; Lung; Mice; Myocytes, Cardiac; Perindopril; Rats; Rats, Sprague-Dawley; Renin; RNA, Messenger; Tissue Kallikreins | 2011 |
Effect of aliskiren in patients with heart failure according to background dose of ACE inhibitor: a retrospective analysis of the Aliskiren Observation of Heart Failure Treatment (ALOFT) trial.
Topics: Aged; Aldosterone; Amides; Angiotensin-Converting Enzyme Inhibitors; Female; Fumarates; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Randomized Controlled Trials as Topic; Renin; Retrospective Studies; Single-Blind Method | 2011 |
Reversibility of the effects of aliskiren in the renal versus systemic circulation.
Topics: Adult; Aged; Aldosterone; Amides; Analysis of Variance; Angiotensin II; Antihypertensive Agents; Blood Pressure; Female; Fumarates; Germany; Half-Life; Humans; Hypertension; Magnetic Resonance Imaging; Male; Middle Aged; Perfusion Imaging; Renal Circulation; Renin; Renin-Angiotensin System; Time Factors; Treatment Outcome; Vasodilation; Vasodilator Agents | 2012 |
Effect of direct renin inhibitor, aliskiren, on peripheral blood monocyte subsets and myocardial salvage in patients with primary acute myocardial infarction.
Topics: Aged; Aldosterone; Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biomarkers; Chi-Square Distribution; Drug Therapy, Combination; Female; Flow Cytometry; Fumarates; GPI-Linked Proteins; Humans; Japan; Lipopolysaccharide Receptors; Magnetic Resonance Imaging; Male; Middle Aged; Monocytes; Myocardial Infarction; Myocardium; Prospective Studies; Receptors, IgG; Renin; Renin-Angiotensin System; Time Factors; Treatment Outcome | 2012 |
Combination of direct renin inhibition with angiotensin type 1 receptor blockade improves aldosterone but does not improve kidney injury in the transgenic Ren2 rat.
Topics: Acute Kidney Injury; Aldosterone; Amides; Angiotensin II Type 1 Receptor Blockers; Animals; Fumarates; Rats; Rats, Sprague-Dawley; Rats, Transgenic; Receptor, Angiotensin, Type 1; Renin; Tetrazoles; Valine; Valsartan | 2012 |
Reduction of aldosterone production improves renal oxidative stress and fibrosis in diabetic rats.
Topics: Aldosterone; Amides; Amlodipine; Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Cyclic GMP; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Dinoprost; Down-Regulation; Fibronectins; Fibrosis; Fumarates; Immunohistochemistry; Kidney; Male; Natriuresis; Nitric Oxide; Oxidative Stress; Rats; Rats, Sprague-Dawley; Time Factors | 2013 |
Renin inhibition and AT(1)R blockade improve metabolic signaling, oxidant stress and myocardial tissue remodeling.
Topics: Aldosterone; Amides; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Cell Size; Drug Interactions; Fibrosis; Fumarates; Mice; Myocardium; Myocytes, Cardiac; Oxidative Stress; Rats; Rats, Sprague-Dawley; Rats, Transgenic; Receptor, Angiotensin, Type 1; Renin; Signal Transduction; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2013 |
Inhibition of the renin-angiotensin system reduces the rise in serum aldosterone in acute coronary syndrome patients with preserved left ventricular function: observations from the AVANT GARDE-TIMI 43 trial.
Topics: Acute Coronary Syndrome; Aldosterone; Amides; Angiotensin-Converting Enzyme Inhibitors; Down-Regulation; Female; Fumarates; Humans; Male; Middle Aged; Renin-Angiotensin System; Retrospective Studies; Tetrazoles; Valine; Valsartan; Ventricular Function, Left | 2013 |
Complement 3 activates the renal renin-angiotensin system by induction of epithelial-to-mesenchymal transition of the nephrotubulus in mice.
Topics: Aldosterone; Amides; Angiotensin II; Animals; Antihypertensive Agents; Complement C3; Epithelial-Mesenchymal Transition; Fumarates; Hypertension; Kidney; Kruppel-Like Transcription Factors; Liver X Receptors; Male; Mice; Mice, Inbred C57BL; Nephrosclerosis; Orphan Nuclear Receptors; Renin; Renin-Angiotensin System; Transforming Growth Factor beta1; Ureteral Obstruction | 2013 |
Deterioration of kidney function by the (pro)renin receptor blocker handle region peptide in aliskiren-treated diabetic transgenic (mRen2)27 rats.
Topics: Aldosterone; Amides; Animals; Blood Pressure; Cyclooxygenase 2; Diabetes Mellitus, Experimental; Disease Models, Animal; Female; Fumarates; Kidney; Male; Oligopeptides; Plasminogen Activator Inhibitor 1; Potassium; Prorenin Receptor; Rats; Rats, Sprague-Dawley; Rats, Transgenic; Receptors, Cell Surface; Renin; Renin-Angiotensin System; Streptozocin | 2014 |
Impact of mineralocorticoid receptor blockade with direct renin inhibition in angiotensin II-dependent hypertensive mice.
Topics: Aldosterone; Amides; Animals; Antihypertensive Agents; Drug Evaluation, Preclinical; Drug Therapy, Combination; Eplerenone; Fumarates; Hypertension; Male; Mice; Mineralocorticoid Receptor Antagonists | 2020 |